NasdaqGM - Nasdaq Real Time Price USD
Evolus, Inc. (EOLS)
9.97
-0.02
(-0.20%)
As of 9:30:00 AM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Moatazedi | President, CEO & Director | 1.67M | 2.09M | 1978 |
| Ms. Sandra Beaver | Chief Financial Officer | 753.21k | -- | 1978 |
| Ms. Tomoko Yamagishi-Dressler | Chief Marketing Officer | 677.37k | -- | 1965 |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development | 811.08k | -- | 1962 |
| Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Jeffrey J. Plumer | General Counsel | -- | -- | -- |
| Mr. Kurt Knab | Senior Vice President of Sales | -- | -- | -- |
| Ms. Jessica Novak | Senior Vice President of Human Resources | -- | -- | -- |
Evolus, Inc.
520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 372
Description
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Corporate Governance
Evolus, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
July 29, 2025 at 10:59 AM UTC - August 4, 2025 at 12:00 PM UTC
Evolus, Inc. Earnings Date
Recent Events
December 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
HROW Harrow, Inc.
24.91
-0.86%
ANIK Anika Therapeutics, Inc.
11.50
+1.55%
AVDL Avadel Pharmaceuticals plc
8.56
+0.35%
AQST Aquestive Therapeutics, Inc.
2.2100
-0.45%
ETON Eton Pharmaceuticals, Inc.
17.06
-0.35%
DVAX Dynavax Technologies Corporation
9.43
+0.32%
ANIP ANI Pharmaceuticals, Inc.
60.45
+0.13%
AYTU Aytu BioPharma, Inc.
2.0654
+52.81%
COLL Collegium Pharmaceutical, Inc.
29.22
+0.50%
AMRX Amneal Pharmaceuticals, Inc.
7.40
+0.61%